Is Inlyta approved for use with Bavencio?
Yes, Inlyta (axitinib) is FDA-approved for use in combination with Bavencio (avelumab) as first-line treatment for advanced renal cell carcinoma (RCC). The regimen, branded as Bavencio plus Inlyta, targets adults with unresectable or metastatic RCC regardless of PD-L1 status.[1][2]
How does the combination work?
Inlyta inhibits vascular endothelial growth factor receptors (VEGFRs) to block tumor blood supply, while Bavencio is a PD-L1 inhibitor that boosts T-cell activity against cancer cells. Together, they attack RCC through complementary angiogenesis and immunotherapy mechanisms.[1][3]
What do clinical trial results show?
The Phase 3 JAVELIN Renal 101 trial tested the combo against sunitinib (Sutent) in 886 patients. Key outcomes at a 44-month median follow-up:
- Median progression-free survival: 13.8 months vs. 8.4 months (HR 0.69).
- Objective response rate: 55.2% vs. 25.5%.
- Overall survival benefit emerging in longer-term data (HR 0.79).[2][4]
Common side effects and management
Patients often face hypertension (from Inlyta), immune-related events like thyroid issues or rash (from Bavencio), and fatigue. Grade 3+ adverse events occurred in 71% on the combo vs. 71% on sunitinib, with discontinuations at 19% vs. 12%. Dose reductions help manage toxicity.[1][2]
Who makes these drugs and what's the dosing?
Pfizer manufactures Inlyta; Pfizer and Merck KGaA (EMD Serono in the US) co-develop Bavencio. Standard dosing: Bavencio 800 mg IV every 2 weeks + Inlyta 5 mg orally twice daily.[1]
When do patents expire for these drugs?
Inlyta's key composition patent (US 7,375,425) expires in 2024, with others extending to 2031; generics are pending FDA approval. Bavencio's patents run to 2031-2033, limiting near-term biosimilars.5
Sources
[1]: Inlyta prescribing information (Pfizer)
[2]: Bavencio prescribing information (Merck)
[3]: FDA approval summary (2021)
[4]: JAVELIN Renal 101 trial (NEJM, 2023 update)